Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC) A Multicenter Placebo-Controlled Randomized Trial: Age Analysis

Seattle Children's Research Hospital and University of Washington, Seattle, WA 98101, USA.
Circulation (Impact Factor: 14.43). 09/2010; 122(11 Suppl):S224-33. DOI: 10.1161/CIRCULATIONAHA.109.926394
Source: PubMed


Triiodothyronine levels decrease in infants and children after cardiopulmonary bypass. We tested the primary hypothesis that triiodothyronine (T3) repletion is safe in this population and produces improvements in postoperative clinical outcome.
The TRICC study was a prospective, multicenter, double-blind, randomized, placebo-controlled trial in children younger than 2 years old undergoing heart surgery with cardiopulmonary bypass. Enrollment was stratified by surgical diagnosis. Time to extubation (TTE) was the primary outcome. Patients received intravenous T3 as Triostat (n=98) or placebo (n=95), and data were analyzed using Cox proportional hazards. Overall, TTE was similar between groups. There were no differences in adverse event rates, including arrhythmia. Prespecified analyses showed a significant interaction between age and treatment (P=0.0012). For patients younger than 5 months, the hazard ratio (chance of extubation) for Triostat was 1.72. (P=0.0216). Placebo median TTE was 98 hours with 95% confidence interval (CI) of 71 to 142 compared to Triostat TTE at 55 hours with CI of 44 to 92. TTE shortening corresponded to a reduction in inotropic agent use and improvement in cardiac function. For children 5 months of age, or older, Triostat produced a significant delay in median TTE: 16 hours (CI, 7-22) for placebo and 20 hours (CI, 16-45) for Triostat and (hazard ratio, 0.60; P=0.0220).
T3 supplementation is safe. Analyses using age stratification indicate that T3 supplementation provides clinical advantages in patients younger than 5 months and no benefit for those older than 5 months. Clinical Trial Registration-URL: Unique identifier: NCT00027417.

Download full-text


Available from: Sara Danzi, Jun 09, 2014
24 Reads
  • Source
    • "For this reason, the CDP did not provide helpful information regarding the therapeutic use of physiological TH in the treatment of cardiac patients. To our knowledge, all pilot interventional studies with the use of synthetic TH conducted in cardiac disease have suggested, on the contrary, its safety [50, 73] and provided some evidence for beneficial effects, mainly in patients undergoing cardiac surgery as well as in those with heart failure with or without cardiogenic shock [50, 73–77]. Type, dosage, and timing of TH-based treatment still remain, however, important open issues which are awaited to be addressed in clinical trials. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nature's models of regeneration provide substantial evidence that a natural healing process may exist in the heart. Analogies existing between the damaged myocardium and the developing heart strongly indicate that regulatory factors which drive embryonic heart development may also control aspects of heart regeneration. In this context, thyroid hormone (TH) which is critical in heart maturation during development appears to have a reparative role in adult life. Thus, changes in TH -thyroid hormone receptor (TR) homeostasis are shown to govern the return of the damaged myocardium to the fetal phenotype. Accordingly, thyroid hormone treatment preferentially rebuilds the injured myocardium by reactivating developmental gene programming. Clinical data provide further support to this experimental evidence and changes in TH levels and in particular a reduction of biologically active triiodothyronine (T3) in plasma after myocardial infarction or during evolution of heart failure, are strongly correlated with patients morbidity and mortality. The potential of TH to regenerate a diseased heart has now been testing in patients with acute myocardial infarction in a phase II, randomized, double blind, placebo-controlled study (the THiRST study).
    Journal of Thyroid Research 06/2011; 2011:958626. DOI:10.4061/2011/958626
  • [Show abstract] [Hide abstract]
    ABSTRACT: The practice of pediatric cardiac intensive care depends on a collaborative effort from all disciplines involved in the care of critically ill pediatric patients with cardiovascular disease. The 8th International Conference of the Pediatric Cardiac Intensive Care Society was reflective of this collaborative effort as experts from several disciplines, including neonatology, critical care, cardiology, neurology, anesthesia and surgery, gathered to discuss the latest advances in the care of pediatric cardiovascular disease, beginning with the fetus and extending into adulthood. Discussion on innovations in imaging and mechanical circulatory devices, the impact of genetics on outcomes, hybrid techniques (that bridge the catheterization laboratory and the operating room), surgery in very low birthweight neonates, and the discussion of adults with congenital heart disease were demonstrative of this collaborative, multidisciplinary effort.
    Expert Review of Cardiovascular Therapy 03/2011; 9(3):291-3. DOI:10.1586/erc.11.3
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract In the post-reperfusion era, molecular and genetic mechanisms of cardioprotection and regeneration represent new therapeutic challenges to limit infarct size and minimize post-ischemic remodeling after acute myocardial infarction (AMI). Activation of cell survival mechanisms can be promoted by the administration of external drugs, stimulation of internal mechanisms, and genetic manipulation to delete or replace pathological genes or enhance gene expression. Among internal cardiovascular regulatory mechanisms, thyroid hormones (THs) may play a fundamental role. TH has a critical role in cardiovascular development and homeostasis in both physiological and pathological conditions. In experimental AMI, TH has been shown to affect cardiac contractility, left ventricular (LV) function, and remodeling. Several experimental studies have clearly shown that THs participate in the regulation of molecular mechanisms of angiogenesis, cardioprotection, cardiac metabolism, and ultimately myocyte regeneration, changes that can reverse left ventricular remodeling by favorably improving myocyte shape and geometry of LV cavity, thus improving systolic and diastolic performance. This review is focused on the role of thyroid on AMI evolution and on the potential novel option of thyroid-related treatment of AMI.
    Annals of Medicine 05/2011; 44(8). DOI:10.3109/07853890.2011.573501 · 3.89 Impact Factor
Show more